Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  DexCom, Inc.    DXCM

DEXCOM, INC.

(DXCM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

DexCom, Inc. : quaterly earnings release

share with twitter share with LinkedIn share with facebook
share via e-mail
10/29/2012 | 09:15am EDT

The company will report its earnings for Q3 2012 on 11/01/2012. Generally, the company reports earnings better than estimates. In recent months, the 13 analysts from Thomson Reuters consensus have revised their EPS estimates downward.


© MarketScreener.com 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on DEXCOM, INC.
03/10DEXCOM INC : Change in Directors or Principal Officers (form 8-K)
AQ
03/06How Lipper Award-winning fund managers are playing coronavirus scare
RE
02/24DEXCOM : to Present at Cowen 40th Annual Healthcare Conference
BU
02/20DEXCOM : G6 Continuous Glucose Monitoring (CGM) System Receives CE Mark for Use ..
BU
02/17DEXCOM : G6® CGM System Now Available In Canada
AQ
02/17DEXCOM : and Companion Medical Announce Collaboration to Integrate Dexcom CGM Da..
AQ
02/17DEXCOM : Announces FDA Clearance of New Dexcom G6 Pro CGM
AQ
02/13DEXCOM : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS..
AQ
02/13DEXCOM : 4Q Earnings Snapshot
AQ
02/13DEXCOM INC : Results of Operations and Financial Condition, Financial Statements..
AQ
More news
Financials (USD)
Sales 2020 1 777 M
EBIT 2020 232 M
Net income 2020 182 M
Finance 2020 36,3 M
Yield 2020 -
P/E ratio 2020 144x
P/E ratio 2021 95,5x
EV / Sales2020 13,5x
EV / Sales2021 10,9x
Capitalization 24 086 M
Chart DEXCOM, INC.
Duration : Period :
DexCom, Inc. Technical Analysis Chart | DXCM | US2521311074 | MarketScreener
Technical analysis trends DEXCOM, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 21
Average target price 284,79  $
Last Close Price 262,96  $
Spread / Highest target 25,5%
Spread / Average Target 8,30%
Spread / Lowest Target -29,6%
EPS Revisions
Managers
NameTitle
Kevin Ronald Sayer Chairman, President & Chief Executive Officer
Quentin S. Blackford Chief Operating & Financial Officer
Andrew K. Balo EVP-Clinical Affairs, Regulatory Strategies
Jacob Leach Chief Technology Officer
Jay S. Skyler Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
DEXCOM, INC.20.22%24 086
MEDTRONIC PLC-20.77%120 468
BAXTER INTERNATIONAL INC.-4.58%40 470
HOYA CORPORATION-2.44%35 360
TERUMO CORPORATION-0.06%25 583
ZIMMER BIOMET HOLDINGS-36.57%19 622